| ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ... Annals of oncology 23 (10), 2479-2516, 2012 | 1850 | 2012 |
| Duration of adjuvant chemotherapy for stage III colon cancer A Grothey, AF Sobrero, AF Shields, T Yoshino, J Paul, J Taieb, ... New England Journal of Medicine 378 (13), 1177-1188, 2018 | 920 | 2018 |
| Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab K Yonesaka, K Zejnullahu, I Okamoto, T Satoh, F Cappuzzo, J Souglakos, ... Science translational medicine 3 (99), 99ra86-99ra86, 2011 | 699 | 2011 |
| FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal … J Souglakos, N Androulakis, K Syrigos, A Polyzos, N Ziras, ... British journal of cancer 94 (6), 798-805, 2006 | 520 | 2006 |
| Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the … J Franko, Q Shi, JP Meyers, TS Maughan, RA Adams, MT Seymour, ... The Lancet Oncology 17 (12), 1709-1719, 2016 | 502 | 2016 |
| BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer M Taron, R Rosell, E Felip, P Mendez, J Souglakos, MS Ronco, C Queralt, ... Human molecular genetics 13 (20), 2443-2449, 2004 | 465 | 2004 |
| Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer J Souglakos, J Philips, R Wang, S Marwah, M Silver, M Tzardi, J Silver, ... British journal of cancer 101 (3), 465-472, 2009 | 373 | 2009 |
| IGF‐I and IGF‐II in relation to colorectal cancer O Manousos, J Souglakos, C Bosetti, A Tzonou, V Chatzidakis, ... International journal of cancer 83 (1), 15-17, 1999 | 241 | 1999 |
| Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC A Kalikaki, A Koutsopoulos, M Trypaki, J Souglakos, E Stathopoulos, ... British journal of cancer 99 (6), 923-929, 2008 | 240 | 2008 |
| DNA repair gene polymorphisms predict favorable clinical outcome in advanced non–small-cell lung cancer A Kalikaki, M Kanaki, H Vassalou, J Souglakos, A Voutsina, ... Clinical lung cancer 10 (2), 118-123, 2009 | 209 | 2009 |
| Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer S Kakolyris, A Giatromanolaki, M Koukourakis, G Powis, J Souglakos, ... Clinical cancer research 7 (10), 3087-3091, 2001 | 204 | 2001 |
| Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients I Boukovinas, C Papadaki, P Mendez, M Taron, D Mavroudis, ... PloS one 3 (11), e3695, 2008 | 188 | 2008 |
| Oral bacteria and intestinal dysbiosis in colorectal cancer I Koliarakis, I Messaritakis, TK Nikolouzakis, G Hamilos, J Souglakos, ... International journal of molecular sciences 20 (17), 4146, 2019 | 185 | 2019 |
| Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised … T André, J Meyerhardt, T Iveson, A Sobrero, T Yoshino, I Souglakos, ... The lancet oncology 21 (12), 1620-1629, 2020 | 184 | 2020 |
| Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients Z Saridaki, M Tzardi, C Papadaki, M Sfakianaki, F Pega, A Kalikaki, ... PloS one 6 (1), e15980, 2011 | 172 | 2011 |
| Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study A Karampeazis, A Voutsina, J Souglakos, N Kentepozidis, S Giassas, ... Cancer 119 (15), 2754-2764, 2013 | 145 | 2013 |
| Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter … J Souglakos, D Mavroudis, S Kakolyris, C Kourousis, N Vardakis, ... Journal of clinical oncology 20 (11), 2651-2657, 2002 | 143 | 2002 |
| Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine J Souglakos, I Boukovinas, M Taron, P Mendez, D Mavroudis, M Tripaki, ... British journal of cancer 98 (10), 1710-1715, 2008 | 140 | 2008 |
| Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study C Emmanouilides, G Sfakiotaki, N Androulakis, K Kalbakis, ... BMC cancer 7, 1-7, 2007 | 136 | 2007 |
| Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial D Mavroudis, C Kourousis, N Androulakis, K Kalbakis, S Agelaki, ... American journal of clinical oncology 23 (4), 341-344, 2000 | 134 | 2000 |
Messaritakis IppokratisUniversity of CreteVerified email at edu.med.uoc.gr
